Breaking News Instant updates and real-time market news.

TYME

Tyme Technologies

$1.50

(0.00%)

08:08
09/30/19
09/30
08:08
09/30/19
08:08

Tyme Technologies presents data from TYME-88-Panc Phase II study

Tyme Technologies announced that its open-label Phase II TYME-88-Panc study evaluating SM-88 as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging overall results and has a well-tolerated safety profile. TYME also announced encouraging Quality of Life data for this challenging patient population. The supporting data from the study were presented at the European Society of Medical Oncology Congress being held on September 27- October 1, 2019 in Barcelona, Spain. As a result of these clinical outcomes, TYME recently launched the multi-center randomized controlled pivotal stage of the TYME-88-Panc trial for use of SM-88 in patients with third-line pancreatic cancer. TYME's lead CMBT candidate, SM-88, was designed to leverage innate changes in cancer metabolism that are fundamental to support the cancer's proliferation. The Warburg Effect, a process that helps most cancer cells adapt to changing conditions, is prevalent across most solid and hematological malignancies impacting energy production and the uptake of non-essential amino acids for cancer growth. SM-88 is a modified dysfunctional form of the amino acid tyrosine. Tyrosine is required for cancer cell growth and as a result, SM-88 is selectively consumed by the cancer cell, causing a disruption of protein synthesis that leads to catastrophic failure and cancer cell death. The results from the multicenter open-label Phase II TYME-88-Panc study involved 49 heavily pretreated patients with radiographically progressive metastatic pancreatic cancer who had significant disease related morbidity before receiving TYME's investigational agent SM-88. More than 80% of patients had received at least two prior lines of therapy. Of the 49 patients, 38 patients were evaluable for efficacy as defined in the protocol. This study is being performed under a TYME IND with input from the FDA prior to study initiation. In this study, based on information available as of April 25, 2019, the median overall survival of the 38 evaluable patients was 6.4 months. Certain efficacy indicators correlated with greater OS, including achieving stable disease or better and decreases in circulating tumor cells. Notably, patients achieving stable disease or better demonstrated a statistically significant improvement in survival with a 92% reduction in risk of death.The clinical benefit response was durable with the majority of these patients remaining in stable disease or better at more than 7 months after receiving treatment with SM-88. In the TYME-88-Panc study, baseline CTCs were an average of 142 cells/4ml. Of the 24 evaluable patients treated with SM-88 who had CTC readings available, 66.7% of those patients showed a median decrease of 63% in CTC levels falling from baseline CTCs to a median of 21 cells/4ml. 42% of those patients with available results reaching an 80% reduction or greater in CTCs demonstrated a 60% decrease in risk of death. A novel radiomics analysis was also conducted. The radiomic analysis of tumor texture correlated with CTCs at baseline. In addition, tumor texture was closely associated with the percentage change in CTCs on treatment and OS. Quality of life assessments were conducted as part of the TYME-88-Panc study. Generally, patients maintained their QOL throughout their treatment with SM-88. Patients reported low levels of GI-related symptoms, which are commonly reported in patients undergoing other treatments for pancreatic cancer. Score for pain and fatigue related questions showed that patients reported generally low levels of these symptoms also. Overall stability of weight was also reported. This is a key finding as patients with pancreatic cancer typically experience noticeable, but unintentional weight loss, which is a clinically meaningful indicator of poor prognosis. As of April 25, 2019, the study reported that SM-88 was well tolerated with only 4.0% of patients who experienced serious adverse events deemed at least possibly related to SM-88. One patient with reported SAEs continued on treatment.

TYME Tyme Technologies
$1.50

(0.00%)

01/18/19
EVER
01/18/19
NO CHANGE
EVER
Evercore's Schimmer likes what he saw in Tyme Technologies data
Evercore ISI analyst Josh Schimmer says that despite today's selloff in the shares, he likes what he saw this morning with Tyme Technologies' update on SM-88. The stock in late morning trading is down 37% to $2.34. The analyst says the drug hit his bar of a low teens response and that management did a good job in highlighting why the data are compelling. Investors have been conditioned to look for a greater than 20% overall response rate in cancer, but that's the wrong hurdle for pancreatic, Schimmer tells investors in a research note. He views SM-88's 12% response rate and clean toxicity as exciting.
01/18/19
HCWC
01/18/19
NO CHANGE
Target $9.5
HCWC
Buy
Tyme selloff unwarranted, brings buying opportunity, says H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth calls the selloff today in shares of Tyme Technologies unwarranted. Overall, the analyst is "very encouraged" by SM-88's "signs of clinical efficacy" in the most rigorous clinical study the company has conducted to date. SM-88 could become one of the most promising therapies for refractory metastatic pancreatic cancer patients, Ramakanth tells investors in a research note. He sees a buying opportunity in today's selloff and reiterates a Buy rating on Tyme Technologies with a $9.50 price target. The stock in midday trading is down 38%, or $1.41, to $2.32.

TODAY'S FREE FLY STORIES

01:45
11/22/19
11/22
01:45
11/22/19
01:45
General news
Asian Market Update: »

Asian Market Update: JGB…

01:45
11/22/19
11/22
01:45
11/22/19
01:45
General news
U.S. consumer sentiment: »

U.S. consumer sentiment:…

20:20
11/21/19
11/21
20:20
11/21/19
20:20
General news
Treasury Market Summary »

Treasury Market Summary:…

LYV

Live Nation

$66.17

-1.55 (-2.29%)

20:08
11/21/19
11/21
20:08
11/21/19
20:08
Periodicals
Live Nation 'looking forward' to taking part in Congress review of ticket market 

Report from Bloomberg.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRH

DiamondRock

$9.86

-0.085 (-0.86%)

19:53
11/21/19
11/21
19:53
11/21/19
19:53
Upgrade
DiamondRock rating change at Wells Fargo »

DiamondRock upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OOMA

Ooma

$11.18

-0.01 (-0.09%)

, IIIV

i3 Verticals

$22.29

-0.52 (-2.28%)

19:18
11/21/19
11/21
19:18
11/21/19
19:18
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ooma…

OOMA

Ooma

$11.18

-0.01 (-0.09%)

IIIV

i3 Verticals

$22.29

-0.52 (-2.28%)

JWN

Nordstrom

$34.29

0.35 (1.03%)

SCVL

Shoe Carnival

$37.18

1.36 (3.80%)

SPLK

Splunk

$126.80

-0.04 (-0.03%)

GPS

Gap

$16.22

-0.05 (-0.31%)

ROST

Ross Stores

$111.81

1.39 (1.26%)

PSTG

Pure Storage

$19.84

-0.22 (-1.10%)

WSM

Williams-Sonoma

$68.76

0.195 (0.28%)

PNNT

PennantPark

$5.95

0.01 (0.17%)

ENTA

Enanta

$63.27

1.55 (2.51%)

INTU

Intuit

$270.01

-3.38 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 22

    Nov

  • 22

    Nov

  • 02

    Dec

  • 02

    Dec

  • 03

    Dec

  • 05

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

  • 10

    Mar

  • 11

    Mar

AES

AES Corp.

$18.50

-0.115 (-0.62%)

19:08
11/21/19
11/21
19:08
11/21/19
19:08
Earnings
AES backs FY19 adjusted EPS view $1.30-$1.38, consensus $1.33 »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

WM

Waste Management

$111.23

-1.305 (-1.16%)

, RSG

Republic Services

$86.78

-0.91 (-1.04%)

19:07
11/21/19
11/21
19:07
11/21/19
19:07
Initiation
Waste Management, Republic Services, Waste Connections, Clean Harbors, Stericycle, Casella Waste, Covanta initiated  »

Jefferies initiates…

WM

Waste Management

$111.23

-1.305 (-1.16%)

RSG

Republic Services

$86.78

-0.91 (-1.04%)

WCN

Waste Connections

$89.54

-0.28 (-0.31%)

CLH

Clean Harbors

$84.70

-0.75 (-0.88%)

SRCL

Stericycle

$62.49

0.76 (1.23%)

CWST

Casella Waste

$43.70

-0.39 (-0.88%)

CVA

Covanta

$14.43

-0.14 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AES

AES Corp.

$18.50

-0.115 (-0.62%)

19:07
11/21/19
11/21
19:07
11/21/19
19:07
Hot Stocks
AES Corp. says PUCO has modified DP&L rates »

The AES Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

ICE

IntercontinentalExchange

$93.89

-0.58 (-0.61%)

, BTC

Bitcoin

$0.00

(0.00%)

19:02
11/21/19
11/21
19:02
11/21/19
19:02
Hot Stocks
ICE announces launch of Bakkt Bitcoin Cash Settled Monthly Futures contract »

Intercontinental Exchange…

ICE

IntercontinentalExchange

$93.89

-0.58 (-0.61%)

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAN

ManpowerGroup

$92.05

-0.355 (-0.38%)

18:51
11/21/19
11/21
18:51
11/21/19
18:51
Initiation
ManpowerGroup initiated at Jefferies »

ManpowerGroup initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHI

Robert Half

$58.01

-0.38 (-0.65%)

18:48
11/21/19
11/21
18:48
11/21/19
18:48
Initiation
Robert Half initiated at Jefferies »

Robert Half initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTZ

Hertz

$15.37

0.265 (1.76%)

18:46
11/21/19
11/21
18:46
11/21/19
18:46
Initiation
Hertz initiated at Jefferies »

Hertz initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$28.71

0.16 (0.56%)

18:44
11/21/19
11/21
18:44
11/21/19
18:44
Initiation
Avis Budget initiated at Jefferies »

Avis Budget initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$39.52

-1.45 (-3.54%)

18:42
11/21/19
11/21
18:42
11/21/19
18:42
Hot Stocks
AMD CEO: The key for us is product generation »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

CTAS

Cintas

$253.61

-5.78 (-2.23%)

, BFAM

Bright Horizons

$148.62

-3.92 (-2.57%)

18:42
11/21/19
11/21
18:42
11/21/19
18:42
Initiation
Cintas, Bright Horizons, Aramark, H&R Block, BrightView, Rollins, ServiceMaster initiated at Jefferies »

Jefferies initiates…

CTAS

Cintas

$253.61

-5.78 (-2.23%)

BFAM

Bright Horizons

$148.62

-3.92 (-2.57%)

ARMK

Aramark

$42.42

-1.37 (-3.13%)

HRB

H&R Block

$24.34

-0.15 (-0.61%)

BV

BrightView

$16.79

-2.525 (-13.08%)

ROL

Rollins

$35.77

-0.8 (-2.19%)

SERV

ServiceMaster

$36.16

-0.42 (-1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 04

    Dec

PINE

Alpine Income Properties

$0.00

(0.00%)

18:34
11/21/19
11/21
18:34
11/21/19
18:34
Syndicate
Alpine Income Properties 7.5M share IPO priced at $19.00 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

OTTW

Ottawa Bancorp

$13.39

-0.39 (-2.83%)

18:28
11/21/19
11/21
18:28
11/21/19
18:28
Hot Stocks
Ottawa Bancorp approves stock buyback of 317,307 shares »

Ottawa Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$149.46

-0.14 (-0.09%)

18:27
11/21/19
11/21
18:27
11/21/19
18:27
Periodicals
Microsoft says granted U.S. license to do business with Huawei, Bloomberg says »

Microsoft said it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 04

    Dec

  • 09

    Dec

SITC

Site Centers

$14.28

-0.275 (-1.89%)

18:24
11/21/19
11/21
18:24
11/21/19
18:24
Upgrade
Site Centers rating change at Stifel »

Site Centers upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Airlines

$90.96

-0.72 (-0.79%)

, BA

Boeing

$366.47

-4.275 (-1.15%)

18:23
11/21/19
11/21
18:23
11/21/19
18:23
Hot Stocks
United Airlines CEO: We don't think we are near a recession »

In an interview on…

UAL

United Airlines

$90.96

-0.72 (-0.79%)

BA

Boeing

$366.47

-4.275 (-1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

FAST

Fastenal

$35.15

-0.1 (-0.28%)

, GWW

Grainger

$312.66

0.305 (0.10%)

18:20
11/21/19
11/21
18:20
11/21/19
18:20
Initiation
Fastenal, Grainger, HD Supply, MSC Industrial, Wesco initiated at Jefferies »

Jefferies initiates…

FAST

Fastenal

$35.15

-0.1 (-0.28%)

GWW

Grainger

$312.66

0.305 (0.10%)

HDS

HD Supply

$39.10

-0.21 (-0.53%)

MSM

MSC Industrial

$73.66

-0.125 (-0.17%)

WCC

Wesco

$53.09

-0.02 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 30

    Jan

SPGI

S&P Global

$264.34

-3.6 (-1.34%)

, INFO

IHS Markit

$71.62

-0.38 (-0.53%)

18:06
11/21/19
11/21
18:06
11/21/19
18:06
Initiation
S&P Global, IHS Markit, Verisk Analytics, Gartner, FactSet, Equifax, TransUnion, CoStar Group initiated at Jefferies »

Jefferies initiates…

SPGI

S&P Global

$264.34

-3.6 (-1.34%)

INFO

IHS Markit

$71.62

-0.38 (-0.53%)

VRSK

Verisk Analytics

$144.45

0.12 (0.08%)

IT

Gartner

$158.00

0.06 (0.04%)

FDS

FactSet

$258.20

-3.65 (-1.39%)

EFX

Equifax

$137.97

-1.15 (-0.83%)

TRU

TransUnion

$84.90

-1.34 (-1.55%)

CSGP

CoStar Group

$587.66

-7.45 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 19

    Dec

  • 19

    Dec

  • 07

    Jan

GPS

Gap

$16.22

-0.05 (-0.31%)

17:59
11/21/19
11/21
17:59
11/21/19
17:59
Periodicals
Gap to pull Old Navy brand from China in early 2020, Reuters reports »

Gap said it does not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

LB

L Brands

$17.18

1.78 (11.56%)

17:50
11/21/19
11/21
17:50
11/21/19
17:50
Hot Stocks
L Brands cancels Victoria's Secret Fashion Show for 'more current platforms' »

The CFO of L Brands,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.